JohnPaulFruehaufMD

Oncology • Orange, CA

Genitourinary Oncology, Hematologic Oncology, Melanoma, Sarcoma

Associate Professor of Medicine, UC Irvine

Join to view full profile

Dr. Fruehauf is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Fruehauf's full profile

Already have an account?

Office
101 The City Dr
Orange, CA 92868
Phone+1 714-456-8000

Fax+1 855-211-3729
Is this information wrong?

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1987 - 1990
University of California (Irvine)Internship, Internal Medicine, 1986 - 1987
Rush Medical College of Rush University Medical CenterClass of 1985

Certifications & Licensure

HI State Medical License 2023 - 2026
IL State Medical License 2023 - 2026
KY State Medical License 2022 - 2025
TX State Medical License 2022 - 2025
AZ State Medical License 2022 - 2025
GA State Medical License 2021 - 2025
WA State Medical License 2022 - 2025
MD State Medical License 1987 - 2024
CA State Medical License 1986 - 2024
NV State Medical License 2022 - 2023
Join now to see all

Awards, Honors, & Recognition

Top Doctors:LA Area Castle Connolly, 2013
Top Doctors:San Diego Area Castle Connolly, 2013
Top Doctors:Southern California Castle Connolly, 2012
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Disulfiram in Patients With Metastatic Melanoma Start of enrollment: 2002 Jan 01
Completed
Phase 1, Phase 2
Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma Start of enrollment: 2003 Apr 01
Completed
Phase 2
Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer Start of enrollment: 2005 Sep 01
Completed
Phase 2
Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy Start of enrollment: 2006 Sep 01
Terminated
Phase 1
Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate Start of enrollment: 2009 Jan 01
Withdrawn
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma Start of enrollment: 2010 Aug 01
Completed
Phase 2
Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma Start of enrollment: 2011 Dec 01
Completed
Phase 2
Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients Start of enrollment: 2010 Dec 01
Completed
Phase 2
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Dec 13
Active, not recruiting
Phase 3
Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer Start of enrollment: 2005 Jan 20
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

11 citations
A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer.
Eric Zhuang, Edward Uchio, Michael B. Lilly, Xiaolin Zi, John P. Fruehauf> ;Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2021 Sep 24
29 citations
HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity
Basmina Parmakhtiar, Robert A. Burger, Jai-Hyun Kim, John P. Fruehauf> ;Molecular Cancer Research. 2019 May 14
14 citations
Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma.
John P. Fruehauf, Monica El-Masry, Katherine Osann, Basmina Parmakhtiar, Maki Yamamoto, James G. Jakowatz> ;Cancer Chemotherapy and Pharmacology. 2018 Jun 25
11 citations
Pharmacokinetics of single-agent axitinib across multiple solid tumor types.
Michael A. Tortorici, Ezra E.W. Cohen, Yazdi K. Pithavala, May Garrett, Ana Ruiz-Garcia, Sinil Kim, John P. Fruehauf> ;Cancer Chemotherapy and Pharmacology. 2014 Oct 22
7 citations
A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder.
Zeynep Eroglu, John P. Fruehauf> ;Cancer Chemotherapy and Pharmacology. 2013 May 1
40 citations
Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis.
Daniel J. Lindner, Yan wu, Rebecca M. Haney, Barbara S. Jacobs, John P. Fruehauf, Ralph J. Tuthill, Ernest C. Borden> ;Matrix Biology. 2013 Mar 11
16 citations
Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent...
Dana M. Chase, M. Sill, Bradley J. Monk, Mark D. Chambers, Kathleen M. Darcy, Ernest S. Han, Barbara J. Buening, Joel I. Sorosky, John P. Fruehauf, Robert A. Burger> ;Gynecologic Oncology. 2012 Sep 1
147 citations
BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced...
Kevin B. Kim, Jeffrey A. Sosman, John P. Fruehauf, Gerald P. Linette, Svetomir N. Markovic, David F. McDermott, Jeffrey S. Weber, Hoa Nguyen, Peter Cheverton, Daniel S...> ;Journal of Clinical Oncology. 2012 Jan 1
84 citations
Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastat...
John P. Fruehauf, Jose Lutzky, David F. McDermott, Charles K. Brown, J. B. Méric, Brad Rosbrook, David R. Shalinsky, K. F. Liau, Andreas G. Niethammer, Sinil Kim, Oliv...> ;Clinical Cancer Research. 2011 Dec 1
8 citations
Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma.
Zeynep Eroglu, Kevin M. Kong, James G. Jakowatz, Wolfram E. Samlowski, John P. Fruehauf> ;Cancer Chemotherapy and Pharmacology. 2011 Jul 19
152 citations
Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
Brian I. Rini, Joan H. Schiller, John P. Fruehauf, Ezra E.W. Cohen, Jamal Tarazi, Brad Rosbrook, Angel H. Bair, Alejandro D. Ricart, Anthony J. Olszanski, Kristen J. L...> ;Clinical Cancer Research. 2011 Jun 1
A single-arm phase II trial evaluating docetaxel, vinorelbine, and GM-CSF in stage IV melanoma.
Fruehauf JP, Eroglu Z, Kong KM, Jakowatz JG, Akerley WL, Samlowski WE> ;J. Clin. Oncol.. 2011-05-20
56 citations
Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels.
Yaxiong Tang, Basmina Parmakhtiar, Anne R. Simoneau, Jun Xie, John P. Fruehauf, Michael B. Lilly, Xiaolin Zi> ;Neoplasia. 2011 Feb 1
8 citations
Immunohistochemical basis for adjuvant anti-angiogenic targeted therapy for renal carcinoid: initial case report.
David S. Finley, Navneet Narula, Vladimir Valera, Maria J. Merino, John P. Fruehauf, Mark Li-cheng Wu, W. Marston Linehan, Ralph V. Clayman> ;Urologic Oncology. 2011 Jan 1
7 citations
Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: A Southwest Oncology Group Study
Leslie M. Randall, Bradley J. Monk, James Moon, Ricardo J. Parker, Muthana Al-Ghazi, Sharon P. Wilczynski, John P. Fruehauf, Maurie Markman, Robert A. Burger> ;Gynecologic Oncology. 2010 Dec 1
55 citations
Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.
Ernest Han, Robert A. Burger, Kathleen M. Darcy, Michael W. Sill, Leslie M. Randall, Dana M. Chase, Basmina Parmakhtiar, Bradley J. Monk, Benjamin E. Greer, Patrick J....> ;Gynecologic Oncology. 2010 Dec 1
80 citations
Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture
Valerie Trapp, Basmina Parmakhtiar, Vartan Papazian, Lyndsay J. Willmott, John P. Fruehauf> ;Angiogenesis. 2010 Oct 7
46 citations
Metronomic Gemcitabine in Combination with Sunitinib Inhibits Multisite Metastasis and Increases Survival in an Orthotopic Model of Pancreatic Cancer
Hop S. Tran Cao, Michael Bouvet, Sharmeela Kaushal, Alex Keleman, Eric Romney, Ginna Kim, John P. Fruehauf, David K. Imagawa, Robert M. Hoffman, Matthew H.G. Katz> ;Molecular Cancer Therapeutics. 2010 Jul 1
48 citations
Prognostic Relevance of Carbonic Anhydrase-IX in High-Risk, Early-Stage Cervical Cancer: A Gynecologic Oncology Group Study
Shu-Yuan Liao, Kathleen M. Darcy, Leslie M. Randall, Chunqiao Tian, Bradley J. Monk, Robert A. Burger, John P. Fruehauf, William A. Peters, Richard J. Stock, Eric J. S...> ;Gynecologic Oncology. 2010 Mar 1
36 citations
Targeted Therapy in Ovarian Cancer
Lyndsay J. Willmott, John P. Fruehauf> ;Journal of Oncology. 2010 Jan 14
6 citations
Redox-related antimelanoma activity of ATN-224.
Valerie Trapp, Kristy Lee, Fernando Donate, Andrew P. Mazar, John P. Fruehauf> ;Melanoma Research. 2009 Dec 1
92 citations
Prediction of drug response in breast cancer using integrative experimental/computational modeling
Hermann B. Frieboes, Mary E. Edgerton, John P. Fruehauf, Felicity R. A. J. Rose, Lisa K. Worrall, Robert A. Gatenby, Mauro Ferrari, Vittorio Cristini> ;Cancer Research. 2009 May 15
72 citations
Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study
Leslie M. Randall, Bradley J. Monk, Kathleen M. Darcy, Chunqiao Tian, Robert A. Burger, Shu-Yuan Liao, William A. Peters, Richard J. Stock, John P. Fruehauf> ;Gynecologic Oncology. 2009 Mar 1
30 citations
The effect of bevacizumab (Avastin) on neuroimaging of brain metastases
Marlon S. Mathews, Mark E. Linskey, Anton N. Hasso, John P. Fruehauf> ;Surgical Neurology. 2008 Dec 1
66 citations
Reactive oxygen species: an Achilles' heel of melanoma?
John P. Fruehauf, Valerie Trapp> ;Expert Review of Anticancer Therapy. 2008 Nov 1
Join now to see all

Grant Support

Novel Biologic Markers Of Treatment Resistance In Locally Advanced Cervical CarciNational Cancer Institute2011–2012
Translational Oncology ProgramNational Cancer Institute2009–2011
Genomics Screening For Antiangiogenesis DrugsNational Cancer Institute2002
Core--Clinical Trials Protocol ReviewNational Cancer Institute2002
Development Of An MDR-1 Resistance-Reversal AssayNational Cancer Institute1993
Development Of A Therapeutic TNF Degradation ProductNational Cancer Institute1993